Cardiol Therapeutics Inc. revenue

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cardiol Therapeutics Inc.: revenue history, annual

Fiscal year	2021Dec 2021
Revenue	63

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Cardiol Therapeutics Inc.	$62,858	—	—
PRF Technologies Ltd.	$17,000	—	—
Akanda Corp.	$258,075	-69.2%	—
Scienture Holdings, Inc.	$821,315	540.6%	-58.5%
60 Degrees Pharmaceuticals, Inc.	$1.1m	73.2%	74.9%
China SXT Pharmaceuticals, Inc.	$1.1m	-34.6%	—

Compare with peers

• PRF Technologies Ltd. revenue
• Akanda Corp. revenue
• Scienture Holdings, Inc. revenue
• 60 Degrees Pharmaceuticals, Inc. revenue
• China SXT Pharmaceuticals, Inc. revenue

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Cardiol Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cardiol Therapeutics Inc.